Hartmut Ney, Konstanz DE
Hartmut Ney, Konstanz DE
Patent application number | Description | Published |
---|---|---|
20080226712 | Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles - The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions. | 09-18-2008 |
20090208571 | Dosage form containing pantoprazole as active ingredient - Dosage forms for the oral administration of the magnesium salt of pantoprazole are described. | 08-20-2009 |
20110060016 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient - Disclosed is a method of treatment of COPD by oral administration of roflumilast. | 03-10-2011 |
20110171303 | DOSAGE FORM CONTAINING (S)-PANTOPRAZOLE AS ACTIVE INGREDIENT - Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described. | 07-14-2011 |
20110251244 | Oral Dosage Form Containing A PDE 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidone As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 10-13-2011 |
20130131123 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - An immediate release solid dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor, comprising a PDE 4 inhibitor that is N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast) or a salt thereof, and one or more suitable pharmaceutical excipients; wherein said dosage form contains 500 μg of the roflumilast or salt thereof. | 05-23-2013 |
20130345265 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 12-26-2013 |
20140031396 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP binder. | 01-30-2014 |
20140031397 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 01-30-2014 |